Clinical trial
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252356 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00252356 |
|---|---|
| Title | Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder |
| Official title | An Eight-Week, Double-Blind, Placebo Controlled, Multicenter Study With Escitalopram (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With MDD |
| Acronym | ORION |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | SR58611A |
| Enrollment | 468 |
| Start date | Sep 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Nov 11, 2005 |
| Last update posted | Mar 12, 2009 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: